TFS Capital’s ANI Pharmaceuticals ANIP Stock Holding History

TFS Capital’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-12,559	Closed	-$701K	–	738
2016 Q2	$701K	Sell	12,559 -24,795	-66%	-$1.21M	0.13%	271
2016 Q1	$1.26M	Buy	37,354 +25,052	+204%	+$850K	0.18%	190
2015 Q4	$555K	Buy	+12,302	New	+$530K	0.06%	394
2015 Q1	–	Sell	-27,824	Closed	-$1.57M	–	945
2014 Q4	$1.57M	Sell	27,824 -27,620	-50%	-$1.22M	0.15%	195
2014 Q3	$1.57M	Buy	+55,444	New	+$1.66M	0.14%	226

Other funds holding ANIP

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

TFS Capital's ANIP Position: Q3 2016 in Review

TFS Capital sold out of ANI Pharmaceuticals (ANIP) in Q3 2016, closing a stake of 12,559 shares — an estimated $701K sold.

TFS Capital first reported a position in ANIP in Q3 2014 and held it in 5 quarters. The position peaked at $1.57M in Q4 2014. 171 funds tracked by Wall St. Rank hold ANIP as of Q3 2016.

TFS Capital reported no remaining ANI Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
TFS Capital sold 12,559 ANI Pharmaceuticals shares in Q3 2016, an estimated $701K.
TFS Capital first reported a position in ANI Pharmaceuticals in Q3 2014 and held it in 5 quarters.
TFS Capital's ANI Pharmaceuticals position peaked at $1.57M in Q4 2014.
171 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.